New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiranās Long-Term Cardiovascular Benefit in ATTR-CM
(NASDAQ:ALNY) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRAĀ® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral sess
Related Questions
How will the presented long-term cardiovascular benefit data for Vutrisiran affect Alnylam's share price and trading volume?
What implications does the 12āmonth OLE data have for Alnylam's future revenue forecasts compared to competing ATTRāCM therapies?
Could the new data trigger any regulatory updates, reimbursement changes, or partnership opportunities that might impact the company's market valuation?